Acelyrin (Acelyrin) Growth Rank : 0 (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Growth Rank?

Acelyrin has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Acelyrin Growth Rank Related Terms

Thank you for viewing the detailed overview of Acelyrin's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Acelyrin (Acelyrin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301

Website

https://www.acelyrin.com

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.

Executives

Shao-lee Lin	director, officer: Chief Executive Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie	officer: Interim CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg	director, 10 percent owner
Henry O Gosebruch	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier	officer: CFO and CBO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim	officer: Chief Legal & Admin. Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston	officer: Chief People Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso	officer: Chief Medical Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker	director	C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p.	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp	director, 10 percent owner, other: See Remarks	1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper	10 percent owner	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria	officer: Chief Operating Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361